Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Awaiting Safety Data For Mirabegron; Expects To File NDA In U.S. In Q2

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas provided an update on development for blockbuster-hopeful mirabegron, and the main theme of its progress appears to be safety, or rather waiting for safety data. The company delayed U.S. and EU filings for the drug on regulatory requests for more safety data to assess cardiovascular risk. The company rescheduled mirabegron's FDA filing for 2Q/FY2011, and now everyone is waiting for full results on additional safety studies

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts